Organization: Emily Mullin, wired.com
Location: Global
Source: Emily Mullin, wired.com
Up until recently, measles vaccination has been so effective that there’s been little medical or financial incentive to develop treatments for the disease. But as measles cases hit a 35-year high and vaccination rates continue to decline in the US, a handful of biotech companies and academic groups have started working on measles treatments for those infected with the virus as well as vulnerable individuals needing short-term protection. It will likely be years, however, before these counterm…
Get Latest Updates: Join our WhatsApp Group